Cardiac fibrosis: Difference between revisions

	WikiDoc Resources for Cardiac fibrosis
Articles
Most recent articles on Cardiac fibrosis Most cited articles on Cardiac fibrosis Review articles on Cardiac fibrosis Articles on Cardiac fibrosis in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Cardiac fibrosis Images of Cardiac fibrosis Photos of Cardiac fibrosis Podcasts & MP3s on Cardiac fibrosis Videos on Cardiac fibrosis
Evidence Based Medicine
Cochrane Collaboration on Cardiac fibrosis Bandolier on Cardiac fibrosis TRIP on Cardiac fibrosis
Clinical Trials
Ongoing Trials on Cardiac fibrosis at Clinical Trials.gov Trial results on Cardiac fibrosis Clinical Trials on Cardiac fibrosis at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Cardiac fibrosis NICE Guidance on Cardiac fibrosis NHS PRODIGY Guidance FDA on Cardiac fibrosis CDC on Cardiac fibrosis
Books
Books on Cardiac fibrosis
News
Cardiac fibrosis in the news Be alerted to news on Cardiac fibrosis News trends on Cardiac fibrosis
Commentary
Blogs on Cardiac fibrosis
Definitions
Definitions of Cardiac fibrosis
Patient Resources / Community
Patient resources on Cardiac fibrosis Discussion groups on Cardiac fibrosis Patient Handouts on Cardiac fibrosis Directions to Hospitals Treating Cardiac fibrosis Risk calculators and risk factors for Cardiac fibrosis
Healthcare Provider Resources
Symptoms of Cardiac fibrosis Causes & Risk Factors for Cardiac fibrosis Diagnostic studies for Cardiac fibrosis Treatment of Cardiac fibrosis
Continuing Medical Education (CME)
CME Programs on Cardiac fibrosis
International
Cardiac fibrosis en Espanol Cardiac fibrosis en Francais
Business
Cardiac fibrosis in the Marketplace Patents on Cardiac fibrosis
Experimental / Informatics
List of terms related to Cardiac fibrosis

VisualWikitext

Latest revision as of 20:12, 14 February 2020

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Niloofarsadaat Eshaghhosseiny, MD [2]

Synonyms and keywords:Davies disease

Overview

Cardiac fibrosis refers to an abnormal thickening of the heart valves due to inappropriate proliferation of cardiac fibroblasts .Endomyocardial fibrosis(EMF) chareacterized by deposite of fibrous and thickening of the endocardium and myocardium ventricles that leading restrictive cardiomyopathy.It is a neglected disorder that usually prodominant in tropical areas of developing and low -income countries.

Historical Perspective

First description for endomyocardial fibrosis was in 1948 by Davies in Uganda.^[1] Endomyocardial fibrosis was first discovered in 1984 in Ugenda.^[1]

There have been several outbreaks of endomycardial fibrosis, including Africa,Asia,and South America.^[1]

Classification

Myocardial fibrosis may be classified into two groups:interstitial fibrosis (diffuse),replacement fibrosis (scar) .^[2] The interstitial fibrosis divided in to two subclasses:reactive and infiltrative.^[3]

Pathophysiology

It is thought that cardiac fibrosis is the result of remodeling of extracellular and deposition of extracellular matrix that causes to impaired muscles function.^[3] Also cardiac fibrosis is mediated by cardial fibrosis include Eosinophilia, Infectious such as toxoplasma, malaria,helminthic parasites,rheumatic fever,Environmental exposure such as cerium ,casava ,Immunologic and Genetic.^[4]^[5]^[6] ^[7]^[8]^[9]

Causes

The most common cause of cardiac fibrosis is cardiac fibrotic scars that usually occure after myocardial infarction . other causes of cardiac fibrotic scars include , hypertensive heart disease,diabetic hypertrophic cardiomyopathy and ,idiopathic dilated cardiomyopathy.^[3]

Differentiating ((Page name)) from other Diseases

cardiac fibrosis must be differentiated from other diseases that cause heart failure ,premature death in children and adults.^[10]

Epidemiology and Demographics

Endomyocardial fibrosis is the most cause of heart failure,that up 20% of cases are in endmic area.^[10]

Recently the incidence of EMF has been decreased.^[10]

In one of the researches in 2008 the prevalence of EMF was 19.8%.^[11]

The incidence of EMF is approximately 10,000,000 people worldwide.^[11]

The incidence of endomycardial fibrosis is more common in Africa,Asia and South America.^[1]

The most cases in Uganda,Mozambique and some west of Africa are Endemic for EMF.^[1] Although sporadic cases have been reported in Congo and Malawi.^[1] In India the most cases are in rain forest area of Kerala State.^[1] In china we can see the high frequency of EMF in Guanxi.^[1] And in south of America , Brazil and Colombia are the most frequent area.^[1]

Patients of all age groups may develop EMF butcommonly affects young adults between 10 to 30 years old with poor socioeconomic status.^[1]

In some researches EMF affects men and women equally but prevalence of EMF in Uganda,is 2-fold higher in women of childbearing age .^[1]

The majority of EMF cases are reported in Africa.^[1]

Risk Factors

Common risk factors in the development of cardiac fibrosis may be occupational, environmental, genetic, and viral.^[3]

Common risk factors in the development of cardiac fibrosis include Obesity, Metabolic dysfunction,DM,HTN.^[12]

Screening

There is insufficient evidence to recommend routine screening for cardiac fibrosis but in high risk individuals or in endemic areas we can use echocardiography as screening.^[13]

Natural History, Complications, and Prognosis

Common complications of cardiac fibrosis include stifness of left ventricle,heart failure,arrihythmias.^[14]

Prognosis is very poor.^[13]

Diagnosis

Diagnostic Study of Choice

The diagnosis and severity of cardiac fibrosis according to classification is made when we have 2 major criteria or 1 major criterion with 2 minor criteria.(table below)^[1]

From Mocumbi AO, Ferreira MB, Sidi D, Yacoub MH.3 A population study of endomyocardial fibrosis in a rural area of Mozambique. N Engl J Med. 2008;359:43–49. Copyright © 2008 Massachusetts Medical Society.
criterion	score
MAJOR CRITERIA
Endomyocardial plaques >2mm in thickness	2
Thin(<1mm) endomyocardial patches affecting >1 ventricular wall	3
Oblitration of the right ventricular or left ventricular apex	4
Thrombi or spontaneous contrast without sever ventricular dysfunction	4
Retraction of right venticular apex (right ventricular apical notch)	4
Atrioventricular valve dysfunction caused by adhession of the valvular apparatus	1-4
MINOR CRITERIA
Thin endomyocardial patches localized to 1 ventricular wall	1
Restrictive flow pattern across mitral or tricuspid valve	2
Pulmonary valve diastolic opening	2
Diffuse thickening of the anterior mitral leaflet	1
Enlarged atrium with normal-sized ventricle	2
M-movment of the interventricular septum and flat posterior wall	1
Enhanced density of the moderator or other intraventricular bands	1

History and Symptoms

EMF symptoms divided in to two phases:Acute , Chronic The most common symptoms of acute include febrile illness ,pancarditis,eosinophilia,dyspenea,itching, pericardial effusion. Symptoms of chronic phase deponds on biventricular or isolated right/left ventricular involvement(RV heart failure/LV heart failure).^[1] In right ventricular involvement most common symptoms are :systemic venous HTN,facial edema,exophtalmos,jugular vein distention,gross hepatomegaly,splenomegaly and abdomonal swelling.^[1]

Physical Examination

Patients with cardiac fibrosis usually appear ill. Common physical examination findings of cardial fibrosis causing heart failure include,facial and periorbital edema, acscites,jvp distention,fever,pericardial friction rub due to pericarditis and non specific signs in chronic phase are clubbing of digits,growth retardation ,testicular atrophy, cachexia.^[1]

Laboratory Findings

Biomarkers of fibrosis can be detected in blood tests.^[2] In 2015 Begon Lopez and teammates have been researched on using collagenouse biomarkers for diagnos of cardiac fibrosis. According to this article there is two type of collagen-derived serum peptids have been related to cardiac fibrosis: Carboxy-terminal propeptide of procollagen type 1(P1CP),Amino-terminal propeptide of procollagen type 3(P3NP).^[15]

Electrocardiogram

An ECG may be helpful in the diagnosis of cardiac fibrosis. Findings on an ECG include RA abnormality,peaking and increased P wave amplitude, if right ventricle involved we will have R wave in lead V1, and AF is common in patients with cardiac fibrosis.^[10]

X-ray

An x-ray may be helpful in the diagnosis of cardiac fibrosis. Findings on an x-ray include cardiomrgaly and may we have silhouette oligemic pulmonary fields.^[10]

Echocardiography or Ultrasound

Findings on an echocardiography suggestive of endomyocardial fibrosis include small ventricle with obliteration of the apex with large atrium .^[10] Oblitration by fibrosis at ventricular apex can change ventricular morphology,that called mushroom sign.^[10]

CT scan

Cardiac calcifications or intracavitary thrombi may be finded in cardiac CT scan.^[1]

MRI

Cardiac MRI may be helpful in the diagnosis of EMF. Findings on MRI diagnostic of EMF include small ventricles with hypertrophy in the apical,also shows hypoperfused myocardial areas and we can see fibrosis in late -gadolinium -enhancement images.^[1]^[10]

Other Imaging Findings

There are no other imaging findings associated with cardiac fibrosis.

Other Diagnostic Studies

There are no other diagnostic studies associated with cardiac fibrosis.

Treatment

Medical Therapy

Supportive therapy of heart failure for EMF includes diuretics, angiotensin-converting enzyme inhibitors with combination therapy with asprin or anticoagulation.^[1]

Surgery

Surgery is the mainstay of treatment for cardiac fibrosis. Compare with medical therapy , surgery can increase patients survival.Surgery of EMF include endocardiotomy and valve replacement or repair.^[10]

Primary Prevention

There are no established measures for the primary prevention of cardiac fibrosis.

Secondary Prevention

Effective measures for the secondary prevention of cardiac fibrosis include screening echocardiography in endemic areas.^[10]

References

↑ ^1.00 ^1.01 ^1.02 ^1.03 ^1.04 ^1.05 ^1.06 ^1.07 ^1.08 ^1.09 ^1.10 ^1.11 ^1.12 ^1.13 ^1.14 ^1.15 ^1.16 ^1.17 ^1.18 Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B; et al. (2016). "Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives". Circulation. 133 (24): 2503–15. doi:10.1161/CIRCULATIONAHA.115.021178. PMID 27297343.
↑ ^2.0 ^2.1 Espeland T, Lunde IG, H Amundsen B, Gullestad L, Aakhus S (2018). "Myocardial fibrosis". Tidsskr Nor Laegeforen. 138 (16). doi:10.4045/tidsskr.17.1027. PMID 30344312.
↑ ^3.0 ^3.1 ^3.2 ^3.3 Hinderer S, Schenke-Layland K (2019). "Cardiac fibrosis - A short review of causes and therapeutic strategies". Adv Drug Deliv Rev. 146: 77–82. doi:10.1016/j.addr.2019.05.011. PMID 31158407.
↑ Weller PF, Bubley GJ (1994). "The idiopathic hypereosinophilic syndrome". Blood. 83 (10): 2759–79. PMID 8180373.
↑ Ijaola O, Falase AO (1990). "Distribution of antibodies against Coxsackie B viruses, arboviruses and Toxoplasma gondii among patients with endomyocardial fibrosis (EMF) compared with normal subjects from EMF endemic and non-endemic zones of Nigeria". Afr J Med Med Sci. 19 (2): 93–103. PMID 2165348.
↑ Valiathan SM, Kartha CC (1990). "Endomyocardial fibrosis--the possible connexion with myocardial levels of magnesium and cerium". Int J Cardiol. 28 (1): 1–5. doi:10.1016/0167-5273(90)90002-m. PMID 2194985.
↑ Sezi CL (1996). "Effects of cassava diet on Cercopithecus aethiops livers: a case for cassava as the cause of both tropical splenomegaly syndrome (TSS) and endomyocardial fibrosis (EMF)". East Afr Med J. 73 (5 Suppl): S24–8. PMID 8756024.
↑ Mocumbi AO, Latif N, Yacoub MH (2010). "Presence of circulating anti-myosin antibodies in endomyocardial fibrosis". PLoS Negl Trop Dis. 4 (4): e661. doi:10.1371/journal.pntd.0000661. PMC 2857887. PMID 20422043.
↑ Lowenthal MN (1978). "Endomyocardial fibrosis: familial and other cases from northern Zambia". Med J Zambia. 12 (1): 2–7. PMID 757895.
↑ ^10.0 ^10.1 ^10.2 ^10.3 ^10.4 ^10.5 ^10.6 ^10.7 ^10.8 ^10.9 Duraes AR, de Souza Lima Bitar Y, Roever L, Neto MG (2019). "Endomyocardial fibrosis: past, present, and future". Heart Fail Rev. doi:10.1007/s10741-019-09848-4. PMID 31414216.
↑ ^11.0 ^11.1 Mocumbi AO, Ferreira MB, Sidi D, Yacoub MH (2008). "A population study of endomyocardial fibrosis in a rural area of Mozambique". N Engl J Med. 359 (1): 43–9. doi:10.1056/NEJMoa0708629. PMID 18596273.
↑ Cavalera M, Wang J, Frangogiannis NG (2014). "Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities". Transl Res. 164 (4): 323–35. doi:10.1016/j.trsl.2014.05.001. PMC 4180761. PMID 24880146.
↑ ^13.0 ^13.1 "Correction". Circulation. 131 (24): e535. 2015. doi:10.1161/CIR.0000000000000219. PMID 26078378.
↑ Ma ZG, Yuan YP, Wu HM, Zhang X, Tang QZ (2018). "Cardiac fibrosis: new insights into the pathogenesis". Int J Biol Sci. 14 (12): 1645–1657. doi:10.7150/ijbs.28103. PMC 6216032. PMID 30416379.
↑ López B, González A, Ravassa S, Beaumont J, Moreno MU, San José G; et al. (2015). "Circulating Biomarkers of Myocardial Fibrosis: The Need for a Reappraisal". J Am Coll Cardiol. 65 (22): 2449–56. doi:10.1016/j.jacc.2015.04.026. PMID 26046739.

Template:WikiDoc Sources

[pmid27297343-1] 1.00 ^1.01 ^1.02 ^1.03 ^1.04 ^1.05 ^1.06 ^1.07 ^1.08 ^1.09 ^1.10 ^1.11 ^1.12 ^1.13 ^1.14 ^1.15 ^1.16 ^1.17 ^1.18 Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B; et al. (2016). "Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives". Circulation. 133 (24): 2503–15. doi:10.1161/CIRCULATIONAHA.115.021178. PMID 27297343.

[pmid30344312-2] 2.0 ^2.1 Espeland T, Lunde IG, H Amundsen B, Gullestad L, Aakhus S (2018). "Myocardial fibrosis". Tidsskr Nor Laegeforen. 138 (16). doi:10.4045/tidsskr.17.1027. PMID 30344312.

[pmid31158407-3] 3.0 ^3.1 ^3.2 ^3.3 Hinderer S, Schenke-Layland K (2019). "Cardiac fibrosis - A short review of causes and therapeutic strategies". Adv Drug Deliv Rev. 146: 77–82. doi:10.1016/j.addr.2019.05.011. PMID 31158407.

[pmid8180373-4] Weller PF, Bubley GJ (1994). "The idiopathic hypereosinophilic syndrome". Blood. 83 (10): 2759–79. PMID 8180373.

[pmid2165348-5] Ijaola O, Falase AO (1990). "Distribution of antibodies against Coxsackie B viruses, arboviruses and Toxoplasma gondii among patients with endomyocardial fibrosis (EMF) compared with normal subjects from EMF endemic and non-endemic zones of Nigeria". Afr J Med Med Sci. 19 (2): 93–103. PMID 2165348.

[pmid2194985-6] Valiathan SM, Kartha CC (1990). "Endomyocardial fibrosis--the possible connexion with myocardial levels of magnesium and cerium". Int J Cardiol. 28 (1): 1–5. doi:10.1016/0167-5273(90)90002-m. PMID 2194985.

[pmid8756024-7] Sezi CL (1996). "Effects of cassava diet on Cercopithecus aethiops livers: a case for cassava as the cause of both tropical splenomegaly syndrome (TSS) and endomyocardial fibrosis (EMF)". East Afr Med J. 73 (5 Suppl): S24–8. PMID 8756024.

[pmid20422043-8] Mocumbi AO, Latif N, Yacoub MH (2010). "Presence of circulating anti-myosin antibodies in endomyocardial fibrosis". PLoS Negl Trop Dis. 4 (4): e661. doi:10.1371/journal.pntd.0000661. PMC 2857887. PMID 20422043.

[pmid757895-9] Lowenthal MN (1978). "Endomyocardial fibrosis: familial and other cases from northern Zambia". Med J Zambia. 12 (1): 2–7. PMID 757895.

[pmid31414216-10] 10.0 ^10.1 ^10.2 ^10.3 ^10.4 ^10.5 ^10.6 ^10.7 ^10.8 ^10.9 Duraes AR, de Souza Lima Bitar Y, Roever L, Neto MG (2019). "Endomyocardial fibrosis: past, present, and future". Heart Fail Rev. doi:10.1007/s10741-019-09848-4. PMID 31414216.

[pmid18596273-11] 11.0 ^11.1 Mocumbi AO, Ferreira MB, Sidi D, Yacoub MH (2008). "A population study of endomyocardial fibrosis in a rural area of Mozambique". N Engl J Med. 359 (1): 43–9. doi:10.1056/NEJMoa0708629. PMID 18596273.

[pmid24880146-12] Cavalera M, Wang J, Frangogiannis NG (2014). "Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities". Transl Res. 164 (4): 323–35. doi:10.1016/j.trsl.2014.05.001. PMC 4180761. PMID 24880146.

[pmid26078378-13] 13.0 ^13.1 "Correction". Circulation. 131 (24): e535. 2015. doi:10.1161/CIR.0000000000000219. PMID 26078378.

[pmid30416379-14] Ma ZG, Yuan YP, Wu HM, Zhang X, Tang QZ (2018). "Cardiac fibrosis: new insights into the pathogenesis". Int J Biol Sci. 14 (12): 1645–1657. doi:10.7150/ijbs.28103. PMC 6216032. PMID 30416379.

[pmid26046739-15] López B, González A, Ravassa S, Beaumont J, Moreno MU, San José G; et al. (2015). "Circulating Biomarkers of Myocardial Fibrosis: The Need for a Reappraisal". J Am Coll Cardiol. 65 (22): 2449–56. doi:10.1016/j.jacc.2015.04.026. PMID 26046739.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

@@ Line 32: / Line 32: @@
 ==Differentiating ((Page name)) from other Diseases==
-cardiac fibrosis must be differentiated from other diseases that cause heart failure,premature death in children and adults.<ref name="pmid31414216">{{cite journal| author=Duraes AR, de Souza Lima Bitar Y, Roever L, Neto MG| title=Endomyocardial fibrosis: past, present, and future. | journal=Heart Fail Rev | year= 2019 | volume=  | issue=  | pages=  | pmid=31414216 | doi=10.1007/s10741-019-09848-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31414216  }} </ref>
+[[Acacia chundra|cardiac fibrosis]] must be differentiated from other diseases that cause [[heart failure]][[Pre-Bötzinger complex|,premature death]] in children and adults.<ref name="pmid31414216">{{cite journal| author=Duraes AR, de Souza Lima Bitar Y, Roever L, Neto MG| title=Endomyocardial fibrosis: past, present, and future. | journal=Heart Fail Rev | year= 2019 | volume=  | issue=  | pages=  | pmid=31414216 | doi=10.1007/s10741-019-09848-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31414216  }} </ref>
 ==Epidemiology and Demographics==
-Endomyocardial fibrosis is the most cause of heart failure,that up 20% of cases are in endmic area.<ref name="pmid31414216">{{cite journal| author=Duraes AR, de Souza Lima Bitar Y, Roever L, Neto MG| title=Endomyocardial fibrosis: past, present, and future. | journal=Heart Fail Rev | year= 2019 | volume=  | issue=  | pages=  | pmid=31414216 | doi=10.1007/s10741-019-09848-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31414216  }} </ref>
+[[Endomyocardial fibrosis]] is the most cause of [[heart failure]],that up 20% of cases are in [[E|endmic area.]]<ref name="pmid31414216">{{cite journal| author=Duraes AR, de Souza Lima Bitar Y, Roever L, Neto MG| title=Endomyocardial fibrosis: past, present, and future. | journal=Heart Fail Rev | year= 2019 | volume=  | issue=  | pages=  | pmid=31414216 | doi=10.1007/s10741-019-09848-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31414216  }} </ref>
-Recently the incidence of EMF has been decreased.<ref name="pmid31414216">{{cite journal| author=Duraes AR, de Souza Lima Bitar Y, Roever L, Neto MG| title=Endomyocardial fibrosis: past, present, and future. | journal=Heart Fail Rev | year= 2019 | volume=  | issue=  | pages=  | pmid=31414216 | doi=10.1007/s10741-019-09848-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31414216  }} </ref>
+Recently the [[Incidence (epidemiology)|incidence]] of [[E-Base|EMF]] has been decreased.<ref name="pmid31414216">{{cite journal| author=Duraes AR, de Souza Lima Bitar Y, Roever L, Neto MG| title=Endomyocardial fibrosis: past, present, and future. | journal=Heart Fail Rev | year= 2019 | volume=  | issue=  | pages=  | pmid=31414216 | doi=10.1007/s10741-019-09848-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31414216  }} </ref>
-In one of the researches in 2008  the prevalence of EMF was 19.8%.<ref name="pmid18596273">{{cite journal| author=Mocumbi AO, Ferreira MB, Sidi D, Yacoub MH| title=A population study of endomyocardial fibrosis in a rural area of Mozambique. | journal=N Engl J Med | year= 2008 | volume= 359 | issue= 1 | pages= 43-9 | pmid=18596273 | doi=10.1056/NEJMoa0708629 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18596273  }} </ref>
+In one of the researches in 2008  the [[prevalence]] of [[E|EMF]] was 19.8%.<ref name="pmid18596273">{{cite journal| author=Mocumbi AO, Ferreira MB, Sidi D, Yacoub MH| title=A population study of endomyocardial fibrosis in a rural area of Mozambique. | journal=N Engl J Med | year= 2008 | volume= 359 | issue= 1 | pages= 43-9 | pmid=18596273 | doi=10.1056/NEJMoa0708629 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18596273  }} </ref>
-The incidence of EMF is approximately 10,000,000 people worldwide.<ref name="pmid18596273">{{cite journal| author=Mocumbi AO, Ferreira MB, Sidi D, Yacoub MH| title=A population study of endomyocardial fibrosis in a rural area of Mozambique. | journal=N Engl J Med | year= 2008 | volume= 359 | issue= 1 | pages= 43-9 | pmid=18596273 | doi=10.1056/NEJMoa0708629 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18596273  }} </ref>
+The [[incidence]] of [[E-Base|EMF]] is approximately 10,000,000 people worldwide.<ref name="pmid18596273">{{cite journal| author=Mocumbi AO, Ferreira MB, Sidi D, Yacoub MH| title=A population study of endomyocardial fibrosis in a rural area of Mozambique. | journal=N Engl J Med | year= 2008 | volume= 359 | issue= 1 | pages= 43-9 | pmid=18596273 | doi=10.1056/NEJMoa0708629 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18596273  }} </ref>
-The incidence of endomycardial fibrosis is more common in Africa,Asia and South America.<ref name="pmid27297343">{{cite journal| author=Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B et al.| title=Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. | journal=Circulation | year= 2016 | volume= 133 | issue= 24 | pages= 2503-15 | pmid=27297343 | doi=10.1161/CIRCULATIONAHA.115.021178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27297343  }} </ref>
-The most cases in Uganda,Mozambique and some west of Africa are Endemic for EMF.<ref name="pmid27297343">{{cite journal| author=Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B et al.| title=Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. | journal=Circulation | year= 2016 | volume= 133 | issue= 24 | pages= 2503-15 | pmid=27297343 | doi=10.1161/CIRCULATIONAHA.115.021178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27297343  }} </ref>
+The [[Incidence (epidemiology)|incidence]] of [[E-Detailing|endomycardial fibrosis]] is more common in Africa,Asia and South America.<ref name="pmid27297343">{{cite journal| author=Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B et al.| title=Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. | journal=Circulation | year= 2016 | volume= 133 | issue= 24 | pages= 2503-15 | pmid=27297343 | doi=10.1161/CIRCULATIONAHA.115.021178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27297343  }} </ref>
-Although sporadic cases have been reported in Congo and Malawi.<ref name="pmid27297343">{{cite journal| author=Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B et al.| title=Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. | journal=Circulation | year= 2016 | volume= 133 | issue= 24 | pages= 2503-15 | pmid=27297343 | doi=10.1161/CIRCULATIONAHA.115.021178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27297343  }} </ref>
-In India the most cases are in rain forest area of Kerala State.<ref name="pmid27297343">{{cite journal| author=Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B et al.| title=Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. | journal=Circulation | year= 2016 | volume= 133 | issue= 24 | pages= 2503-15 | pmid=27297343 | doi=10.1161/CIRCULATIONAHA.115.021178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27297343  }} </ref>
+The most cases in [[U-quadratic distribution|Uganda,Mozambique]] and some west of Africa are [[Endemic goitre|Endemic]] for EMF.<ref name="pmid27297343">{{cite journal| author=Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B et al.| title=Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. | journal=Circulation | year= 2016 | volume= 133 | issue= 24 | pages= 2503-15 | pmid=27297343 | doi=10.1161/CIRCULATIONAHA.115.021178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27297343  }} </ref>
-In china we can see the high frequency of EMF in Guanxi.<ref name="pmid27297343">{{cite journal| author=Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B et al.| title=Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. | journal=Circulation | year= 2016 | volume= 133 | issue= 24 | pages= 2503-15 | pmid=27297343 | doi=10.1161/CIRCULATIONAHA.115.021178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27297343  }} </ref>
+Although [[Sporadic fatal insomnia|sporadic]] cases have been reported in [[C|Congo and Malawi]].<ref name="pmid27297343">{{cite journal| author=Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B et al.| title=Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. | journal=Circulation | year= 2016 | volume= 133 | issue= 24 | pages= 2503-15 | pmid=27297343 | doi=10.1161/CIRCULATIONAHA.115.021178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27297343  }} </ref>
-And in south of America , Brazil and Colombia are the most frequent area.<ref name="pmid27297343">{{cite journal| author=Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B et al.| title=Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. | journal=Circulation | year= 2016 | volume= 133 | issue= 24 | pages= 2503-15 | pmid=27297343 | doi=10.1161/CIRCULATIONAHA.115.021178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27297343  }} </ref>
+In [[India Health Initiative|India]] the most cases are in rain forest area of Kerala State.<ref name="pmid27297343">{{cite journal| author=Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B et al.| title=Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. | journal=Circulation | year= 2016 | volume= 133 | issue= 24 | pages= 2503-15 | pmid=27297343 | doi=10.1161/CIRCULATIONAHA.115.021178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27297343  }} </ref>
+In [[China Medical Technologies|china]] we can see the high frequency of [[E-Base|EMF]] in [[G+C ratio|Guanxi]].<ref name="pmid27297343">{{cite journal| author=Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B et al.| title=Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. | journal=Circulation | year= 2016 | volume= 133 | issue= 24 | pages= 2503-15 | pmid=27297343 | doi=10.1161/CIRCULATIONAHA.115.021178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27297343  }} </ref>
+And in [[South African Health Ministry|south of America , Brazil and Colombia]] are the most frequent area.<ref name="pmid27297343">{{cite journal| author=Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B et al.| title=Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. | journal=Circulation | year= 2016 | volume= 133 | issue= 24 | pages= 2503-15 | pmid=27297343 | doi=10.1161/CIRCULATIONAHA.115.021178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27297343  }} </ref>
 Patients of all age groups may develop EMF butcommonly affects young adults between 10 to 30 years old with poor socioeconomic status.<ref name="pmid27297343">{{cite journal| author=Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B et al.| title=Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. | journal=Circulation | year= 2016 | volume= 133 | issue= 24 | pages= 2503-15 | pmid=27297343 | doi=10.1161/CIRCULATIONAHA.115.021178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27297343  }} </ref>
-In some researches EMF affects men and women equally but prevalence of EMF in Uganda,is 2-fold higher in women of childbearing age .<ref name="pmid27297343">{{cite journal| author=Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B et al.| title=Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. | journal=Circulation | year= 2016 | volume= 133 | issue= 24 | pages= 2503-15 | pmid=27297343 | doi=10.1161/CIRCULATIONAHA.115.021178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27297343  }} </ref>
+In some researches EMF affects men and women equally but [[prevalence]] of [[E-Glades|EMF]] in [[Uganda Virus Research Institute|Uganda]],is 2-fold higher in women of childbearing age .<ref name="pmid27297343">{{cite journal| author=Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B et al.| title=Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. | journal=Circulation | year= 2016 | volume= 133 | issue= 24 | pages= 2503-15 | pmid=27297343 | doi=10.1161/CIRCULATIONAHA.115.021178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27297343  }} </ref>
-The majority of EMF  cases are reported in Africa.<ref name="pmid27297343">{{cite journal| author=Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B et al.| title=Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. | journal=Circulation | year= 2016 | volume= 133 | issue= 24 | pages= 2503-15 | pmid=27297343 | doi=10.1161/CIRCULATIONAHA.115.021178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27297343  }} </ref>
+The majority of [[E-Glades|EMF]]  cases are reported in [[African-Caribbean Leukaemia Trust|Africa]].<ref name="pmid27297343">{{cite journal| author=Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B et al.| title=Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. | journal=Circulation | year= 2016 | volume= 133 | issue= 24 | pages= 2503-15 | pmid=27297343 | doi=10.1161/CIRCULATIONAHA.115.021178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27297343  }} </ref>
 ==Risk Factors==
-Common risk factors in the development of cardiac fibrosis may be occupational, environmental, genetic, and viral.<ref name="pmid31158407">{{cite journal| author=Hinderer S, Schenke-Layland K| title=Cardiac fibrosis - A short review of causes and therapeutic strategies. | journal=Adv Drug Deliv Rev | year= 2019 | volume= 146 | issue=  | pages= 77-82 | pmid=31158407 | doi=10.1016/j.addr.2019.05.011 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31158407  }} </ref>
+Common [[Risk factor|risk factors]] in the development of [[Celiac disease|cardiac fibrosis]] may be occupational, environmental, [[genetic]], and viral.<ref name="pmid31158407">{{cite journal| author=Hinderer S, Schenke-Layland K| title=Cardiac fibrosis - A short review of causes and therapeutic strategies. | journal=Adv Drug Deliv Rev | year= 2019 | volume= 146 | issue=  | pages= 77-82 | pmid=31158407 | doi=10.1016/j.addr.2019.05.011 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31158407  }} </ref>
-Common risk factors in the development of cardiac fibrosis include Obesity, Metabolic dysfunction,DM,HTN.<ref name="pmid24880146">{{cite journal| author=Cavalera M, Wang J, Frangogiannis NG| title=Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities. | journal=Transl Res | year= 2014 | volume= 164 | issue= 4 | pages= 323-35 | pmid=24880146 | doi=10.1016/j.trsl.2014.05.001 | pmc=4180761 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24880146  }} </ref>
+Common [[risk factors]] in the development of [[C(o)eliac sprue|cardiac fibrosis]] include [[Obesity-hypotonia syndrome|Obesity]], [[Multivitamin|Metabolic dysfunction,DM,HTN.]]<ref name="pmid24880146">{{cite journal| author=Cavalera M, Wang J, Frangogiannis NG| title=Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities. | journal=Transl Res | year= 2014 | volume= 164 | issue= 4 | pages= 323-35 | pmid=24880146 | doi=10.1016/j.trsl.2014.05.001 | pmc=4180761 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24880146  }} </ref>
 ==Screening==
-There is insufficient evidence to recommend routine screening for cardiac fibrosis but in high risk individuals or in endemic areas we can use echocardiography as screening.<ref name="pmid26078378">{{cite journal| author=| title=Correction. | journal=Circulation | year= 2015 | volume= 131 | issue= 24 | pages= e535 | pmid=26078378 | doi=10.1161/CIR.0000000000000219 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26078378  }} </ref>
+There is insufficient evidence to recommend routine [[S'mores Grahams|screening]] for [[C(o)eliac sprue|cardiac fibrosis]] but in high risk individuals or in [[endemic]] areas we can use [[echocardiography]] as [[Screening (medicine)|screening]].<ref name="pmid26078378">{{cite journal| author=| title=Correction. | journal=Circulation | year= 2015 | volume= 131 | issue= 24 | pages= e535 | pmid=26078378 | doi=10.1161/CIR.0000000000000219 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26078378  }} </ref>
 ==Natural History, Complications, and Prognosis==
-Common complications of cardiac fibrosis  include stifness of left ventricle,heart failure,arrihythmias.<ref name="pmid30416379">{{cite journal| author=Ma ZG, Yuan YP, Wu HM, Zhang X, Tang QZ| title=Cardiac fibrosis: new insights into the pathogenesis. | journal=Int J Biol Sci | year= 2018 | volume= 14 | issue= 12 | pages= 1645-1657 | pmid=30416379 | doi=10.7150/ijbs.28103 | pmc=6216032 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30416379  }} </ref>
+Common [[complications]] of cardiac fibrosis  include [[S&M|stifness of left ventricle]],[[H&C|heart failure,arrihythmias.]]<ref name="pmid30416379">{{cite journal| author=Ma ZG, Yuan YP, Wu HM, Zhang X, Tang QZ| title=Cardiac fibrosis: new insights into the pathogenesis. | journal=Int J Biol Sci | year= 2018 | volume= 14 | issue= 12 | pages= 1645-1657 | pmid=30416379 | doi=10.7150/ijbs.28103 | pmc=6216032 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30416379  }} </ref>
-Prognosis is very poor.<ref name="pmid26078378">{{cite journal| author=| title=Correction. | journal=Circulation | year= 2015 | volume= 131 | issue= 24 | pages= e535 | pmid=26078378 | doi=10.1161/CIR.0000000000000219 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26078378  }} </ref>
+[[Prognosis]] is very poor.<ref name="pmid26078378">{{cite journal| author=| title=Correction. | journal=Circulation | year= 2015 | volume= 131 | issue= 24 | pages= e535 | pmid=26078378 | doi=10.1161/CIR.0000000000000219 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26078378  }} </ref>
 ==Diagnosis==
 ===Diagnostic Study of Choice===
-The diagnosis and severity of cardiac fibrosis  according to classification is made when we have 2 major criteria or 1 major criterion with 2 minor criteria.(table below)<ref name="pmid27297343">{{cite journal| author=Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B | display-authors=etal| title=Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. | journal=Circulation | year= 2016 | volume= 133 | issue= 24 | pages= 2503-15 | pmid=27297343 | doi=10.1161/CIRCULATIONAHA.115.021178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27297343  }} </ref>
+The diagnosis and severity of [[C(o)eliac sprue|cardiac fibrosis]]  according to classification is made when we have 2 [[M-Cresol|major criteria]] or 1 [[M-Cresol|major criterion]] with 2 [[M-Cresol|minor criteria]].(table below)<ref name="pmid27297343">{{cite journal| author=Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B | display-authors=etal| title=Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. | journal=Circulation | year= 2016 | volume= 133 | issue= 24 | pages= 2503-15 | pmid=27297343 | doi=10.1161/CIRCULATIONAHA.115.021178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27297343  }} </ref>
 <br />
 {| class="wikitable"
 |+
-From Mocumbi AO, Ferreira MB, Sidi D, Yacoub MH.3 A population study
+[[F-2 (psychedelic)|From Mocumbi AO, Ferreira MB, Sidi D, Yacoub MH.3 A population study
 of endomyocardial fibrosis in a rural area of Mozambique. N Engl J Med. 2008;359:43–49. Copyright © 2008
-Massachusetts Medical Society.
+Massachusetts Medical Society.]]
 !criterion
 !score
 |-
-| colspan="2" |MAJOR CRITERIA
+| colspan="2" |[[M-Caps|MAJOR]] [[C(o)eliac sprue|CRITERIA]]
 |-
-|Endomyocardial plaques >2mm in thickness
+|[[E-Base|Endomyocardial plaques]] >2mm in thickness
 |2
 |-
-|Thin(<1mm) endomyocardial patches affecting >1 ventricular wall
+|Thin(<1mm) [[E-Detailing|endomyocardial patches]] affecting >1 [[Ventricular Fibrillation|ventricular wall]]
 |3
 |-
-|Oblitration of the right ventricular or left ventricular apex
+|Oblitration of the right ventricular or left ventricular [[apex]]
 |4
 |-
-|Thrombi or spontaneous contrast without sever ventricular dysfunction
+|[[Thrombasthenia|Thromb]]<nowiki/>i or spontaneous contrast without sever ventricular dysfunction
 |4
 |-
-|Retraction of right venticular apex (right ventricular apical notch)
+|[[R-4066|Retraction of right venticular apex]] (right ventricular apical notch)
 |4
 |-
-|Atrioventricular valve dysfunction caused by adhession of the valvular apparatus
+|[[Alpha,alpha-phosphotrehalase|Atrioventricular valve dysfunction]] caused by adhession of the valvular apparatus
 |1-4
 |-
-| colspan="2" |MINOR CRITERIA
+| colspan="2" |[[M-Caps|MINOR CRITERIA]]
 |-
-|Thin endomyocardial patches localized to 1 ventricular wall
+|Thin [[E-Base|endomyocardial patches]] localized to 1 ventricular wall
 |1
 |-
-|Restrictive flow pattern across mitral or tricuspid valve
+|[[Restrictive lung disease|Restrictive flow]] pattern across [[Mitral regurgitation|mitral or tricuspid]] valve
 |2
 |-
-|Pulmonary valve  diastolic opening
+|[[Pulmonary]] valve  [[Diastolic|diastolic opening]]
 |2
 |-
-|Diffuse thickening of the anterior mitral leaflet
+|Diffuse thickening of the [[Anterior|anterior mitral leaflet]]
 |1
 |-
-|Enlarged atrium with normal-sized ventricle
+|[[E-Detailing|Enlarged atrium]] with normal-sized ventricle
 |2
 |-
-|M-movment of the interventricular septum and flat posterior wall
+|[[Multivitamin|M-movment]] of the [[interventricular septum]] and flat posterior wall
 |1
 |-
-|Enhanced density of the moderator or other intraventricular bands
+|Enhanced density of the moderator or other [[Intraventricular|intraventricular bands]]
 |1
 |}
 ===History and Symptoms===
-EMF symptoms divided in to two phases:Acute , Chronic
+[[E-Detailing|EMF symptoms]] divided in to two phases:Acute , Chronic
-The most common symptoms of acute  include febrile illness ,pancarditis,eosinophilia,dyspenea,itching, pericardial effusion.
+The most common symptoms of acute  include [[Febrile|febrile illness]] [[Multivitamin|,pancarditis]],[[E-Glades|eosinophilia,dyspenea,itching, pericardial effusion]].
-Symptoms of chronic phase deponds on biventricular  or isolated  right/left ventricular involvement(RV heart failure/LV heart failure).<ref name="pmid27297343">{{cite journal| author=Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B | display-authors=etal| title=Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. | journal=Circulation | year= 2016 | volume= 133 | issue= 24 | pages= 2503-15 | pmid=27297343 | doi=10.1161/CIRCULATIONAHA.115.021178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27297343  }} </ref>
+Symptoms of chronic phase deponds on biventricular  or isolated  right/left ventricular involvement[[R-406A|(RV heart failure/LV heart failure]]).<ref name="pmid27297343">{{cite journal| author=Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B | display-authors=etal| title=Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. | journal=Circulation | year= 2016 | volume= 133 | issue= 24 | pages= 2503-15 | pmid=27297343 | doi=10.1161/CIRCULATIONAHA.115.021178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27297343  }} </ref>
-In right ventricular involvement  most common symptoms are :systemic venous HTN,facial edema,exophtalmos,jugular vein distention,gross hepatomegaly,splenomegaly and abdomonal swelling.<ref name="pmid27297343">{{cite journal| author=Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B | display-authors=etal| title=Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. | journal=Circulation | year= 2016 | volume= 133 | issue= 24 | pages= 2503-15 | pmid=27297343 | doi=10.1161/CIRCULATIONAHA.115.021178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27297343  }} </ref>
+In right ventricular involvement  most common symptoms are :[[System justification|systemic venous HTN]],[[F-22 (psychedelic)|facial edema,exophtalmos,jugular vein distention,gross hepatomegaly,splenomegaly and abdomonal swelling.]]<ref name="pmid27297343">{{cite journal| author=Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B | display-authors=etal| title=Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. | journal=Circulation | year= 2016 | volume= 133 | issue= 24 | pages= 2503-15 | pmid=27297343 | doi=10.1161/CIRCULATIONAHA.115.021178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27297343  }} </ref>
 ===Physical Examination===
-Patients with cardiac fibrosis usually appear ill.
+Patients with [[17 alpha-hydroxylase deficiency|cardiac fibrosis]] usually appear [[Illness|ill]].
-Common physical examination findings of cardial fibrosis causing heart failure include,facial and periorbital edema, acscites,jvp distention,fever,pericardial friction rub due to pericarditis and non specific signs in chronic phase are clubbing of digits,growth retardation ,testicular atrophy, cachexia.<ref name="pmid27297343">{{cite journal| author=Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B | display-authors=etal| title=Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. | journal=Circulation | year= 2016 | volume= 133 | issue= 24 | pages= 2503-15 | pmid=27297343 | doi=10.1161/CIRCULATIONAHA.115.021178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27297343  }} </ref>
+Common [[physical examination]] findings of [[C(o)eliac sprue|cardial fibrosis]] causing [[heart failure]] include[[F-2 (psychedelic)|,facial and periorbital edema]], [[A-CHAMP|acscites]],[[J&j|jvp distention,fever,pericardial friction rub]] due to [[Pericarditis (patient information)|pericarditis]] and non specific [[signs]] in chronic phase are [[Clubbing|clubbin]]<nowiki/>g of digits,[[growth retardation]] ,[[testicular atrophy]], [[C(o)eliac sprue|cachexia]].<ref name="pmid27297343">{{cite journal| author=Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B | display-authors=etal| title=Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. | journal=Circulation | year= 2016 | volume= 133 | issue= 24 | pages= 2503-15 | pmid=27297343 | doi=10.1161/CIRCULATIONAHA.115.021178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27297343  }} </ref>
 ===Laboratory Findings===
-Biomarkers of fibrosis can be detected in blood tests.<ref name="pmid30344312">{{cite journal| author=Espeland T, Lunde IG, H Amundsen B, Gullestad L, Aakhus S| title=Myocardial fibrosis. | journal=Tidsskr Nor Laegeforen | year= 2018 | volume= 138 | issue= 16 | pages=  | pmid=30344312 | doi=10.4045/tidsskr.17.1027 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30344312  }} </ref>
+[[Biomarkers of cardiac injury|Biomarkers]] of [[F-22 (psychedelic)|fibrosis]] can be detected in [[blood tests]].<ref name="pmid30344312">{{cite journal| author=Espeland T, Lunde IG, H Amundsen B, Gullestad L, Aakhus S| title=Myocardial fibrosis. | journal=Tidsskr Nor Laegeforen | year= 2018 | volume= 138 | issue= 16 | pages=  | pmid=30344312 | doi=10.4045/tidsskr.17.1027 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30344312  }} </ref>
-In 2015 Begon Lopez and teammates have been researched on using collagenouse biomarkers for diagnos of cardiac fibrosis.
+In 2015 Begon Lopez and teammates have been researched on using collagenouse biomarkers for diagnos of [[C|cardiac fibrosis]].
-According to this article there is two type of collagen-derived serum peptids have been related to cardiac fibrosis:
+According to this article there is two type of [[Collagen-vascular diseases|collagen-]]<nowiki/>derived [[Serum-ascities albumin gradient|serum peptid]]<nowiki/>s have been related to [[Calcium-aluminium-rich inclusion|cardiac fibrosi]]<nowiki/>s:
-Carboxy-terminal propeptide of procollagen type 1(P1CP),Amino-terminal propeptide of procollagen type 3(P3NP).<ref name="pmid26046739">{{cite journal| author=López B, González A, Ravassa S, Beaumont J, Moreno MU, San José G | display-authors=etal| title=Circulating Biomarkers of Myocardial Fibrosis: The Need for a Reappraisal. | journal=J Am Coll Cardiol | year= 2015 | volume= 65 | issue= 22 | pages= 2449-56 | pmid=26046739 | doi=10.1016/j.jacc.2015.04.026 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26046739  }} </ref>
+[[Ca|Carboxy-terminal propeptide]] of [[C|procollagen type 1(P1CP),Amino-terminal propeptide of procollagen type 3(P3NP).]]<ref name="pmid26046739">{{cite journal| author=López B, González A, Ravassa S, Beaumont J, Moreno MU, San José G | display-authors=etal| title=Circulating Biomarkers of Myocardial Fibrosis: The Need for a Reappraisal. | journal=J Am Coll Cardiol | year= 2015 | volume= 65 | issue= 22 | pages= 2449-56 | pmid=26046739 | doi=10.1016/j.jacc.2015.04.026 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26046739  }} </ref>
 ===Electrocardiogram===
-An ECG may be helpful in the diagnosis of cardiac fibrosis. Findings on an ECG include RA abnormality,peaking and increased P wave amplitude, if right ventricle involved we will have R wave in lead V1, and AF is common in patients with cardiac fibrosis.<ref name="pmid31414216">{{cite journal| author=Duraes AR, de Souza Lima Bitar Y, Roever L, Neto MG| title=Endomyocardial fibrosis: past, present, and future. | journal=Heart Fail Rev | year= 2019 | volume=  | issue=  | pages=  | pmid=31414216 | doi=10.1007/s10741-019-09848-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31414216  }} </ref>
+An [[ECG]] may be helpful in the [[diagnosis]] of [[C(o)eliac sprue|cardiac fibrosis]]. Findings on an [[ECG]] include [[J&j|RA abnormality,peaking and increased P wave amplitude, if right ventricle involved we will have R wave in lead V1,]] and [[AF]] is common in patients with [[Celiac disease|cardiac fibrosis]].<ref name="pmid31414216">{{cite journal| author=Duraes AR, de Souza Lima Bitar Y, Roever L, Neto MG| title=Endomyocardial fibrosis: past, present, and future. | journal=Heart Fail Rev | year= 2019 | volume=  | issue=  | pages=  | pmid=31414216 | doi=10.1007/s10741-019-09848-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31414216  }} </ref>
 ===X-ray===
-An x-ray may be helpful in the diagnosis of cardiac fibrosis. Findings on an x-ray  include cardiomrgaly and may we have silhouette oligemic pulmonary fields.<ref name="pmid31414216">{{cite journal| author=Duraes AR, de Souza Lima Bitar Y, Roever L, Neto MG| title=Endomyocardial fibrosis: past, present, and future. | journal=Heart Fail Rev | year= 2019 | volume=  | issue=  | pages=  | pmid=31414216 | doi=10.1007/s10741-019-09848-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31414216  }} </ref>
+An [[X-rays|x-ray]] may be helpful in the diagnosis of [[C|cardiac fibrosi]]<nowiki/>s. Findings on an [[x-ray]]  include [[Calcium-aluminium-rich inclusion|cardiomrgaly]] and may we have [[S'mores Grahams|silhouette oligemic pulmonary]] fields.<ref name="pmid31414216">{{cite journal| author=Duraes AR, de Souza Lima Bitar Y, Roever L, Neto MG| title=Endomyocardial fibrosis: past, present, and future. | journal=Heart Fail Rev | year= 2019 | volume=  | issue=  | pages=  | pmid=31414216 | doi=10.1007/s10741-019-09848-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31414216  }} </ref>
 ===Echocardiography or Ultrasound===
-Findings on an echocardiography suggestive of endomyocardial fibrosis include small ventricle with obliteration of the apex with large atrium .<ref name="pmid31414216">{{cite journal| author=Duraes AR, de Souza Lima Bitar Y, Roever L, Neto MG| title=Endomyocardial fibrosis: past, present, and future. | journal=Heart Fail Rev | year= 2019 | volume=  | issue=  | pages=  | pmid=31414216 | doi=10.1007/s10741-019-09848-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31414216  }} </ref>
+Findings on an [[Echocardiographer|echocardiograph]]<nowiki/>y suggestive of [[endomyocardial fibrosis]] include small ventricle with obliteration of the apex with large atrium .<ref name="pmid31414216">{{cite journal| author=Duraes AR, de Souza Lima Bitar Y, Roever L, Neto MG| title=Endomyocardial fibrosis: past, present, and future. | journal=Heart Fail Rev | year= 2019 | volume=  | issue=  | pages=  | pmid=31414216 | doi=10.1007/s10741-019-09848-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31414216  }} </ref>
-Oblitration by fibrosis at ventricular apex can change ventricular  morphology,that called mushroom sign.<ref name="pmid31414216">{{cite journal| author=Duraes AR, de Souza Lima Bitar Y, Roever L, Neto MG| title=Endomyocardial fibrosis: past, present, and future. | journal=Heart Fail Rev | year= 2019 | volume=  | issue=  | pages=  | pmid=31414216 | doi=10.1007/s10741-019-09848-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31414216  }} </ref>
+Oblitration by fibrosis at ventricular apex can change ventricular  morphology,that called [[Mushrooms|mushroom sign]].<ref name="pmid31414216">{{cite journal| author=Duraes AR, de Souza Lima Bitar Y, Roever L, Neto MG| title=Endomyocardial fibrosis: past, present, and future. | journal=Heart Fail Rev | year= 2019 | volume=  | issue=  | pages=  | pmid=31414216 | doi=10.1007/s10741-019-09848-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31414216  }} </ref>
 ===CT scan===
-Cardiac calcifications or intracavitary thrombi may be finded in cardiac  CT scan.<ref name="pmid27297343">{{cite journal| author=Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B | display-authors=etal| title=Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. | journal=Circulation | year= 2016 | volume= 133 | issue= 24 | pages= 2503-15 | pmid=27297343 | doi=10.1161/CIRCULATIONAHA.115.021178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27297343  }} </ref>
+Cardiac [[Calcific tendinitis|calcifications]] or [[Cromoglicate|intracavitary thromb]]<nowiki/>i may be finded in cardiac  [[CT scan]].<ref name="pmid27297343">{{cite journal| author=Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B | display-authors=etal| title=Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. | journal=Circulation | year= 2016 | volume= 133 | issue= 24 | pages= 2503-15 | pmid=27297343 | doi=10.1161/CIRCULATIONAHA.115.021178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27297343  }} </ref>
 ===MRI===
-Cardiac MRI may be helpful in the diagnosis of EMF. Findings on MRI diagnostic of EMF include small ventricles with hypertrophy in the apical,also shows hypoperfused myocardial areas and  we can see fibrosis in late -gadolinium -enhancement
+Cardiac [[MRI]] may be helpful in the diagnosis of [[E-Base|EMF]]. Findings on [[MRI]] diagnostic of EMF include small ventricles with [[Hypertrophy (medical)|hypertrophy]] in the apical,also shows [[Diatrizoic acid|hypoperfused myocardial]] areas and  we can see [[fibrosis]] in [[L-2-amino-4-chloropent-4-enoate dehydrochlorinase|late -gadolinium -enhancement
-images.<ref name="pmid27297343">{{cite journal| author=Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B | display-authors=etal| title=Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. | journal=Circulation | year= 2016 | volume= 133 | issue= 24 | pages= 2503-15 | pmid=27297343 | doi=10.1161/CIRCULATIONAHA.115.021178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27297343  }} </ref><ref name="pmid31414216">{{cite journal| author=Duraes AR, de Souza Lima Bitar Y, Roever L, Neto MG| title=Endomyocardial fibrosis: past, present, and future. | journal=Heart Fail Rev | year= 2019 | volume=  | issue=  | pages=  | pmid=31414216 | doi=10.1007/s10741-019-09848-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31414216  }} </ref>
+images.]]<ref name="pmid27297343">{{cite journal| author=Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B | display-authors=etal| title=Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. | journal=Circulation | year= 2016 | volume= 133 | issue= 24 | pages= 2503-15 | pmid=27297343 | doi=10.1161/CIRCULATIONAHA.115.021178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27297343  }} </ref><ref name="pmid31414216">{{cite journal| author=Duraes AR, de Souza Lima Bitar Y, Roever L, Neto MG| title=Endomyocardial fibrosis: past, present, and future. | journal=Heart Fail Rev | year= 2019 | volume=  | issue=  | pages=  | pmid=31414216 | doi=10.1007/s10741-019-09848-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31414216  }} </ref>
 ===Other Imaging Findings===
@@ Line 177: / Line 178: @@
 ===Medical Therapy===
-Supportive therapy  of heart failure for EMF includes diuretics, angiotensin-converting enzyme inhibitors with combination therapy with asprin or anticoagulation.<ref name="pmid27297343">{{cite journal| author=Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B | display-authors=etal| title=Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. | journal=Circulation | year= 2016 | volume= 133 | issue= 24 | pages= 2503-15 | pmid=27297343 | doi=10.1161/CIRCULATIONAHA.115.021178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27297343  }} </ref>
+[[Support|Supportive therapy]]  of [[Congestive heart failure|heart failure]] for EMF includes [[Diuretic|diuretics]], [[angiotensin-converting enzyme inhibitors]] with combination therapy with [[Aspirin|asprin]] or [[Alpha,alpha-phosphotrehalase|anticoagulation]].<ref name="pmid27297343">{{cite journal| author=Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B | display-authors=etal| title=Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. | journal=Circulation | year= 2016 | volume= 133 | issue= 24 | pages= 2503-15 | pmid=27297343 | doi=10.1161/CIRCULATIONAHA.115.021178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27297343  }} </ref>
 ===Surgery===
-Surgery is the mainstay of treatment for cardiac fibrosis.
+Surgery is the mainstay of treatment for [[Celiac disease|cardiac fibrosis]].
-Compare with medical therapy , surgery can increase patients survival.Surgery of EMF include endocardiotomy and valve replacement or repair.<ref name="pmid31414216">{{cite journal| author=Duraes AR, de Souza Lima Bitar Y, Roever L, Neto MG| title=Endomyocardial fibrosis: past, present, and future. | journal=Heart Fail Rev | year= 2019 | volume=  | issue=  | pages=  | pmid=31414216 | doi=10.1007/s10741-019-09848-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31414216  }} </ref>
+Compare with medical therapy , surgery can increase patients [[Survival function|survival]].Surgery of [[EMB|EMF]] include [[E|endocardiotom]]<nowiki/>y and [[valve replacement]] or repair.<ref name="pmid31414216">{{cite journal| author=Duraes AR, de Souza Lima Bitar Y, Roever L, Neto MG| title=Endomyocardial fibrosis: past, present, and future. | journal=Heart Fail Rev | year= 2019 | volume=  | issue=  | pages=  | pmid=31414216 | doi=10.1007/s10741-019-09848-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31414216  }} </ref>
 ===Primary Prevention===
-There are no established measures for the primary prevention of cardiac fibrosis.
+There are no established measures for the primary prevention of [[C(o)eliac sprue|cardiac fibrosis]].
 ===Secondary Prevention===
-Effective measures for the secondary prevention of cardiac fibrosis include screening echocardiography in endemic areas.<ref name="pmid31414216">{{cite journal| author=Duraes AR, de Souza Lima Bitar Y, Roever L, Neto MG| title=Endomyocardial fibrosis: past, present, and future. | journal=Heart Fail Rev | year= 2019 | volume=  | issue=  | pages=  | pmid=31414216 | doi=10.1007/s10741-019-09848-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31414216  }} </ref>
+Effective measures for the [[secondary prevention]] of [[Celiac disease|cardiac fibrosis]] include [[Screening (medicine)|screening]] [[Echocardiography and ultrasound|echocardiography]] in [[endemic]] areas.<ref name="pmid31414216">{{cite journal| author=Duraes AR, de Souza Lima Bitar Y, Roever L, Neto MG| title=Endomyocardial fibrosis: past, present, and future. | journal=Heart Fail Rev | year= 2019 | volume=  | issue=  | pages=  | pmid=31414216 | doi=10.1007/s10741-019-09848-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31414216  }} </ref>
 ==References==
@@ Line 194: / Line 195: @@
 {{WikiDoc Help Menu}}
 {{WikiDoc Sources}}
-==Pathophysiology==
-These cells secrete [[collagen]], and normally function to provide structural support for the heart. When over activated this process causes thickening and fibrosis, primarily on the [[tricuspid valve]], but also occurring on the [[pulmonary valve]], eventually leading to right-sided [[heart failure]].
-Certain diseases such as gastrointestinal [[carcinoid]] tumors, which release large amounts of [[serotonin]] into the blood, produce a characteristic pattern of mostly right sided cardiac fibrosis which can be identified at autopsy. This pathology has also been seen in certain african tribes who eat foods containing excess amounts of serotonin.
-Some appetite suppressant drugs such as [[fenfluramine]] and [[chlorphentermine]] induce a similar pattern of cardiac fibrosis, by over-stimulating 5HT<sub>2B</sub> receptors on the cardiac fibroblast cells. These drugs consequently tended to cause increased risk of heart valve damage and subsequent [[heart failure]], which eventually led to them being withdrawn from the market.
-A compound found in red wine, [[resveratrol]] has been found to slow down the development of cardiac fibrosis.
-{{WikiDoc Help Menu}}
-{{WikiDoc Sources}}
-[[CME Category::Cardiology]]
-[[Category:Cardiology]]
-[[Category:Gross pathology]]